MAB Discovery

MAB Discovery GMBH

Disease Biology Driven Antibody Discovery to Deliver Superior Immunotherapeutics

Monoclonal antibodies are the most successful modality in the market of innovative therapeutic products. Within the top 10 products (2015) there are 6 monoclonal antibody brands with $51.5 billion sales, representing 62% of the top 10 overall sales. However, the successful discovery and development of novel antibodies remains a very rare event and is an extremely costly endeavour. MAB Discovery has been founded with the aim to provide a novel approach for the discovery of monoclonal antibodies that will significantly improve the probability of success for product development.